Trial Profile
Efficacy and safety of simeprevir plus pegylated intereferon combination therapy for HCV genotype 1 patients with chronic renal failure
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Jul 2017
Price :
$35
*
At a glance
- Drugs Simeprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 29 Jun 2017 Status changed from recruiting to completed.
- 06 Jan 2014 New trial record